MCRB Share Price | Seres Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Seres Therapeutics, Inc.?

Market Cap: As of Jun 18, Seres Therapeutics, Inc. has a market capitalization of 63.92 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Seres Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -66.86 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 13.78 million and total assets of 139.81 million.

Q: What does Seres Therapeutics, Inc. do?

Overview: Seres Therapeutics, Inc. is a microbiome therapeutics platform company engaged in developing Ecobiotic microbiome therapeutics to restore health by repairing dysbiotic microbiomes, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.Financial Snapshot: Most recent Net Profit: 33 Million (Quarterly Results - Mar 2025) Market cap: USD 63.92 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.99 Return on Equity: -132.49% Price to Book: 1.27Contact Details: Address: 200 Sidney St, CAMBRIDGE MA: 02139-4218 Tel: ['1 617 9459626', '1 617 2033467'] Fax: 1 302 6555049 Website: http://serestherapeutics.com/

Q: Is Seres Therapeutics, Inc. overvalued or undervalued?

As of 8 July 2024, the valuation grade for Seres Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company is overvalued given its current financial metrics, particularly with a Price to Book Value of 1.42 and an EV to Capital Employed ratio of 22.07, which suggests that the market is pricing the company at a premium despite its poor performance. Additionally, the negative ROCE of -11917.50% and ROE of -132.49% highlight the company's struggles in generating returns for shareholders.In comparison to its peers, Seres Therapeutics has a less favorable valuation profile, with Terns Pharmaceuticals, Inc. showing a more negative P/E of -6.9440 and Humacyte, Inc. at -1.8479, indicating that these companies are also facing challenges but are priced lower relative to their earnings potential. Over the past year, Seres Therapeutics has underperformed the S&P 500, returning -14.14% compared to the index's 17.14%, reinforcing the notion that the stock is not a compelling investment at its current valuation.

Q: Is Seres Therapeutics, Inc. technically bullish or bearish?

As of 19 August 2025, the technical trend for Seres Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. Bollinger Bands are bullish on the weekly and mildly bullish on the monthly. The KST shows a bullish trend weekly and mildly bullish monthly, while the OBV is mildly bearish weekly but mildly bullish monthly. In terms of returns, the stock has outperformed the S&P 500 over the past week with a return of 2.62% compared to the S&P 500's 1.05%, but it has underperformed over the past month, year-to-date, and year. Overall, the current technical stance is bullish, driven primarily by the positive signals from MACD and moving averages.

Results Declared: Seres Therapeutics, Inc. has declared results on 12 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

15.61 k

Shareholding (Dec 2025)

FII

3.82%

Held by 26 FIIs

DII

72.1%

Held by 12 DIIs

Promoter

12.80%

How big is Seres Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Seres Therapeutics, Inc. has a market capitalization of 63.92 million, with net sales of 0.00 million and a net profit of -66.86 million over the last four quarters. The company reported shareholder's funds of 13.78 million and total assets of 139.81 million as of Dec 24.

View full answer

What does Seres Therapeutics, Inc. do?

22-Jun-2025

Seres Therapeutics, Inc. is a microbiome therapeutics company focused on developing Ecobiotic therapies to restore health by repairing dysbiotic microbiomes. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of approximately $63.92 million.

View full answer

Who are in the management team of Seres Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Seres Therapeutics, Inc. includes Independent Chairman Mr. Stephen Berenson, President and CEO Mr. Eric Shaff, and several Independent Directors: Dr. Dennis Ausiello, Mr. Gregory Behar, Mr. Paul Biondi, Dr. Willard Dere, and Mr. Kurt Graves.

View full answer

Is Seres Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of July 8, 2024, Seres Therapeutics, Inc. is considered overvalued and has deteriorated to a "does not qualify" rating due to poor financial metrics, including a negative ROCE and ROE, and has underperformed the S&P 500, making it a less appealing investment compared to its peers.

View full answer

Is Seres Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 19, 2025, Seres Therapeutics, Inc. shows a bullish technical trend, supported by positive MACD and moving averages, despite underperforming the S&P 500 over the past month and year.

View full answer

Compare Seres Therapeutics, Inc. with Similar Stocks

Nuvation Bio, Inc.MeiraGTx Holdings Plc Zura Bio Ltd.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 83 Million (Micro Cap)

P/E

15.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.86

Return on Equity

12.34%

Price to Book

1.90

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Dec 2025)

Net Profit:

-15 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-40.26%

6 Months

-52.86%

1 Year

-35.91%

2 Years

-40.56%

3 Years

60.63%

4 Years

-93.99%

5 Years

-97.61%

Seres Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-56.80%

EBIT Growth (5y)

-3.35%

EBIT to Interest (avg)

-23.74

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.99

Sales to Capital Employed (avg)

0.98

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

34.82%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.90

EV to EBIT

-0.44

EV to EBITDA

-0.47

EV to Capital Employed

7.58

EV to Sales

45.30

PEG Ratio

0.10

Dividend Yield

ROCE (Latest)

-1729.87%

ROE (Latest)

12.34%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 22 Schemes (11.28%)

Foreign Institutions

Held by 26 Foreign Institutions (3.82%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs -100.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 1.92% vs 62.14% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.40",
          "val2": "-25.70",
          "chgp": "28.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.30",
          "val2": "-15.60",
          "chgp": "1.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-44,239.70%",
          "val2": "0.00%",
          "chgp": "-4,423.97%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 104.53% vs 33.82% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-89.80",
          "val2": "-103.40",
          "chgp": "13.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-3.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "5.70",
          "val2": "-125.80",
          "chgp": "104.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-119,101.40%",
          "val2": "0.00%",
          "chgp": "-11,910.14%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.40

0.00

Operating Profit (PBDIT) excl Other Income

-18.40

-25.70

28.40%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-15.30

-15.60

1.92%

Operating Profit Margin (Excl OI)

-44,239.70%

0.00%

-4,423.97%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs -100.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 1.92% vs 62.14% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.80

0.00

Operating Profit (PBDIT) excl Other Income

-89.80

-103.40

13.15%

Interest

0.00

Exceptional Items

0.00

-3.30

100.00%

Consolidate Net Profit

5.70

-125.80

104.53%

Operating Profit Margin (Excl OI)

-119,101.40%

0.00%

-11,910.14%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 104.53% vs 33.82% in Dec 2024

All Annual Results

Company CV

About Seres Therapeutics, Inc.

Seres Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.

Company Coordinates

Company Details

200 Sidney St , CAMBRIDGE MA : 02139-4218

Tel: 1 617 94596261 617 2033467

http://serestherapeutics.com/

Registrar Details